Increasing Significance of MRD Testing in the Healthcare Industry

22 Aug 2022

The global minimal residual disease (MRD) testing market is within the swiftly evolving dynamic stage of healthcare medical technologies, which opens sufficient possibilities for diagnostic and existing healthcare technological agencies.  

The MRD happens due to asmall number of cancer cells left in the body after treatment. These cells can potentially come back and cause relapse in the patients. 

The MRD testing marketplace is pushed by certain factors, including the growing prevalence of hematologic malignancies, growing consumer awareness for tailor-made therapy, studies investment from the National Cancer Institute, and growing disposable profits in rising economies. 

The agenciesworking with the international MRD testing market are currently focusing more on disease-specific and personalized diagnostic kits to cater to testing and enhance detection outcomes.

Also, primarily inclusive ARUP Laboratories, Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Cergentis B.V, F. Hoffmann-La Roche Ltd, and Guardant Health are investing closely in studies and improvements for their respective testing products. 

Impact of MRD Testing on the Current Testing Market Paradigm

With the increasing global attention on treating hematological malignancies, the predominant market is growing novel diagnostic tests that are substantially impacting the increase of the MRD testing market. 

Diagnostic evolution in associate diagnostics and liquid biopsy via molecular procedures such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) has enabled molecular diagnostic experts to go into this marketplace seamlessly. 

Following FDA approvals of clonoSEQ and Signatera, that is in vitro diagnosticuses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) toidentify and quantify rearranged IgH (VDJ), IgH (DJ), Irks, and IgL receptor gene sequences. Focusing on imposing hematological malignancies, essential corporations are trying to make investments withinside the subject of MRD. The market witnessed about 35 synergistic developments between January 2018 and May 2022. 

According to the BIS Research report, MRD testing market is projected to reach $2.61billion by 2027 from $1.08billion in 2021, at a compound annual growth rate (CAGR) of 14.53%. 


The worldwide MRD testing market has witnessed significant improvement with the help of key industry players working in the market.Some of these improvements include synergistic activities, product approvals, product launches and updates, mergers and acquisitions, commercial enterprise enlargement and funding, and several other developments (ex: Medicare coverage).

Recent Developments in the Global MRD Testing Market 

•    In November 2021, Palmetto GBA’s Molecular Diagnostics Program (MolDX) showed a local coverage determination that supported the Medicare insurance for clonoSEQ in sufferers with B-molecular acute lymphoblastic leukemia (ALL), a couple of myelomas (MM), and continual lymphocytic leukemia (CLL) for tracking minimum residual sickness.    

•    In February 2021, Natera, Inc. and Personalis, Inc. partnered the subject of personalized oncology via combining Personalis’ NeXT tumor profiling and diagnostic merchandise with Natera’s personalized ctDNA platform Signatera for remedy tracking and molecular residual sickness assessment.

•    In May 2021, Invivoscribe, Inc. introduced licensing of key software programs and new MRD medical services. The company’s LymphoTrack Enterprise Software supported an excessive quantity of clients to satisfy ever-growing testing demands.

•    In October 2021, Inivata Limited, a subsidiary of NeoGenomics, Inc., entered a medical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, to use Inivata's InVisionFirst-Lung and RaDaR liquid biopsy assays in separate studies. 

Market Segmentation by Technology: With the recent developments in molecular diagnostic technology, the turnaround time and usual cost have decreased with accelerated sensitivity and accuracy. Significant advances are being witnessed with the implementation of multiple sensitive and quantitative assessments. Some of the brand-new technologies encompass NGS and low-cost PCR gadgets. NGS technology allows for the study of all the genomic regions of each pathology in a single step and is independent of the mutation site, length, and sequence. 

Market Segmentation by Application: The global MRD testing market (through the application) is widely segmented into hematological malignancy and strong tumor applications. Hematological malignancy, however, leads the market with 94.39% of the market share in 2021. 

Market Segmentation by End-User: End-user of the MRD marketgenerally consists of hospitals and strong point clinics, studies institutions, diagnostic laboratories, and others. 

Although hospitals and strong point clinics were at the forefront of this growing technology that comprises numerous ancillaries for advanced organic and chemical studies, the applicability of MRD tests has been vast amongst institutions. Other end-users, including out-patient clinics and most cancer clinics, make a considerable contribution to the global MRD testing market.


Conclusion

Testing for MRD can assist healthcare practitioners in distinguishing between sufferers who need additional (or different) remedies from patients that do not. This knowledge also can doubtlessly be manual treatment selections and enhance improved patient outcomes. Minimal residual disorder testing can assist in the following ways:

•    Identify proper responsesto the treatment of cancer patients. 
•    Confirm and reveal remissions.
•    Find most cancers recurrence earlier than different tests.
•    Identify sufferers who can be at a higher risk of relapse.
•    Identify sufferers who might also additionally want to restart the treatment.
•    Identify sufferers who might also gain advantage from different treatments, along with stem molecular transplantation or aggregate therapy. 

Although maximum diagnostic products for the testing of MRD encompasses clonoSEQ, QXDx BCR-ABL %IS Kit, Oncomine BCR IGH SR Assay, DNA, and AVENIO ctDNA surveillance kits; there is a greatdemand for greater testing tools that can be extraordinarily sensitive, specific, and cost-effective. 

 
 

Twitter Feeds

 

OUR CLIENTS